These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29110556)

  • 1. The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.
    Frieder J; Kivelevitch D; Fiore CT; Saad S; Menter A
    Expert Rev Clin Immunol; 2018 Jan; 14(1):1-19. PubMed ID: 29110556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies in psoriasis: a systematic review.
    Lee EB; Amin M; Bhutani T; Wu JJ
    Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis: from Pathogenesis to Targeted Therapies.
    Conrad C; Gilliet M
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):102-113. PubMed ID: 29349534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab for treating plaque psoriasis.
    Rothstein B; Gottlieb A
    Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
    J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP; Lewis VJ; Finlay AY
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.
    Tan WS; Kelly S; Pitzalis C
    Expert Rev Clin Immunol; 2017 Mar; 13(3):207-222. PubMed ID: 27690678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA; Menter A; Feldman S; Kimel M; Harnam N; Willian MK
    Health Qual Life Outcomes; 2008 Oct; 6():75. PubMed ID: 18831744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.
    Tonini A; Gualtieri B; Panduri S; Romanelli M; Chiricozzi A
    Expert Opin Biol Ther; 2018 Feb; 18(2):135-148. PubMed ID: 29103330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
    Reich K; Griffiths CE
    Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR; Emer J
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of TNF-α antagonists on the quality of life in selected skin diseases.
    Gisondi P; Girolomoni G
    G Ital Dermatol Venereol; 2013 Jun; 148(3):243-8. PubMed ID: 23670060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of IL 23 in the treatment of psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.